Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / MYC overactivity enables DNA repair and chemotherapy resistance in tumours

Overactive MYC helps tumors fix DNA breaks and resist chemotherapy, study finds

medicalxpress - A protein best known for driving cancer growth also helps damaged tumor cells survive by repairing their DNA, according to a new study that could influence how some cancers are treated.

AI Summary: New research reveals overactive MYC drives tumor cells to repair DNA breaks more efficiently, enabling resistance to chemotherapy. By illuminating the repair pathways MYC hijacks, the study identifies potential targets to reverse resistance and improve treatment responses — because apparently cancers read the manual on how to survive your best shot.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #genetics

MYC hijacks DNA repair to enable chemo resistance

7 days / medicalxpress

11 days / medicalxpress

14 days / sciencedaily

15 days / medicalxpress


Other molecular drivers of chemoresistance and genome instability

11 days / medicalxpress

11 days / medicalxpress

11 days / medicalxpress


Tumor cell death and immunity shape chemotherapy outcomes

10 days / medicalxpress

11 days / medicalxpress

13 days / medicalxpress


All Other Stories

3 days / oncodaily

3 days / medicalxpress

6 days / medicalxpress

7 days / sciencedaily


Back to Top / Monday, May 18, 2026, 12:21 am / permalink 23934 / 17 stories in 13 days /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories



Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 43 hrs

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity / 2 months

CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 15 days

Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 20 days

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 46 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Olfaction, Hearing Loss, Long COVID, Medicare Advantage (not listed) and look for the RSS link.



NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.